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Decreased Urinary Histamine Metabolite after Successful PUV A 
Treatment of Urticaria Pigmentosa 
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From the Departments of Clinical Physiology (G.G.) and Dermatology (G.R. and G.S.), Sahlg renslw sjuhhllset, University of Goteborg, 
Goteborg, Sweden. 
The effect of PUV A therapy on pruritus, the skin mast 
cell population and histamine metabolism has been stud-
ied in 3 patients with urticaria pigmentosa and manifes-
tations of systemic mastocytosis. Relief of itch was found 
concomitant with a significant decrease of the major 
histamine metabolite I-methyl-4-imidazoleacetic acid in 
the urine. The decrease occurred during the first 2 mo 
after starting PUV A therapy and was sustained during 
an observation period of 3 mo after discontinuation of 
the treatment. At this time a reduction of the number of 
mast cells was found in skin biopsy specimens. No evi-
dence of acute histamine release in association with 
PUV A treatment was obtained. These results suggest 
that this effective new treatment for urticaria pigmen-
tosa reduces the histamine turnover in the skin by · in-
hibiting mast cell proliferation. 
UrticaJ·ia pigmentosa (UP) is a dermal proliferation and 
accumulation of mast cells while systemic mastocytosis implies 
an infiltration of noncutaneous tissues as well. The lesions of 
UP may be either solitary or generalized. Prmitus is a disabling 
symptom of the disease, which often presents with urtication, 
dermographism and flushing. Treatment with corticosteroids, 
antihistamines and histamine liberators only occasionally re-
lieves pruritus. 
A recent report by Cluistophers' et al [1] described regression 
of the disabling prmitus of UP after treatment with 8-methox-
ypsoralen and UVA-light (PUVA). The underlying mechanisr:n 
for the apparent effect of this new therapy is not known. In this 
s tudy we are able to confirm Christophel's' et al [1] encouraging 
results but also report a substantial decrease of I-methyl-4-
imidazoleacetic acid (MeImAA), the major histamine metabo-
lite in the urine, about 2 mo after stru-ting PUV A therapy. As 
MeImAA is exclusively derived from histamine and accounts 
for 70-80% of the total amount of histamine metabolized in the 
body [2], this study offered a possibili ty to relate histamine 
tmnover to the different systemic manifestations of mastocy-
tosis and to the effect of PUV A treatment on the number of 
mast cells in the skin . 
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PATIENTS AND METHODS 
Three adu lt patients with well -known UP since ma ny years were 
studied. The diagnosis was confi.rmed clinically and by skin histology. 
Fw-ther investigations of the pat ients revealed systemic mastocytosis 
as shown by ""Tc bone scan, sternal puncture and liver scin tigraphy. 
Relevant clinical details and the com se a fter treatment are summarized 
in the Table. The patients received 0.5 mg of 8-methoxypsoralen per 
kg body weigh t 2 ill· before UVA treatment (PUVA 4000, Waldma nn, 
Germa ny) . The ini t ial UVA dose of 1 J / cm" was adjusted to the 
minimal phototoxic dose, which was ma intained a ll through the t reat-
ment period. The fina l dose was 5 J / cm" for GS, 15 J / cm2 for LS a nd 
6 J / cm2 for EG. The accumulated dose fo r the 3 patients stuclied is 
given in the Table. GS was treated twice a week for 34 weeks while 
PUV A was given twice a week for 10 week in LS a nd for 18 weeks in 
EG, thereafter these patients received their treatment once a week for 
11 and 14 weeks respectively. In all 3 patients PUVA treatment wa 
then discontinued dming the summer. 
S hin H istology 
Biopsy specimens were obtained from hyperpigmented patches of 
the ~horacic skin before and 10-12 weeks after in terrupt ing P UVA 
therapy. 4-mm cutaneous punch biopsies were procured. For a naes-
thesia 1% xylocaine with adrena line was injected in the periphery of 
the area to be biopsied. E mbedding was performed in para ffin and 2-3 
11m thick sections were stained wi th Giemsa's reagent. 
Urine was collected from 8 AM in 24 hl" periods a nd usua lly on 2 
consecutive days, during PUVA therapy on the day of PUVA treatment 
and on the day before. The PUVA thera py wa given between 8 a nd 12 
AM. To avoid bacterial growth, the urine was ac id ified with hydrochloric 
acid to a pH of less than 2. During the days of study the patients ate a 
standardized diet with a defined , low histamine content [2]. 
Histamine in urine was determined with the enzymatic double 
isotope method described by Beaven, Jacobsen, a nd Horakova [3] as 
modified by Aadland, Berstad, a nd Granerus [4]. 
l-methyl-4- imida.zoleacetic acid (MelmAA) was converted to the 
ethyl ester, which was extracted with ether and estimated by thin-layer 
chromatography according to the method of Granerus and Magnusson 
[5], with sligh t moclifications [6]. T he variabili ty between excretion 
values from con ecutive days was dete rmined according to t he formula 
J'r, d" / 2n and found to be 1.61 mg/ 24 hr, corresponding to a coefficient 
of varia tion of 16%, which is in the same order as reported ear lier in 
patients with polycythemia vera [7]. 
In Fig 1 urinary levels of MeImAA are expres ed in term of individ-
ua l mean creatinine excretion to correct for variable urine collection. 
RESULTS 
Regression of the itch was observ,ed wi thin 2 weeks after 
starting PUV A therapy and all the patients were symptomless 
after 3-6 weeks. The hyperpigmented maculae of UP seemed 
to fade dming treatment in all patients but did not disapperu·. 
Any change in the systemic manifestations of mastocytosis wa 
not possible to measure. 
The 3 patients differed markedly regarding the urinru·y ex-
cretion of MeIrnAA. Before PUV A treatment there was a large 
increase in GS, a moderate increase in LS and a slight increase 
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Clinical details of the 3 m.astocytosis patients studied 
Patient! A!:e (yr) M anifesLaLion of Pruritus 
sex Present At onset mastocytosis At onset PU VA2mo 3 mo after PUVA 
Total UVA 
dose (J /cm' ) 
GS/ F 70 51 Hepato-splenomeg- Severe Symptomless M ild 148 
a ly and bone scan 
abnormali t ies 
LS/ M 49 42 Bone marrow inftl- Moderate Symptomless Symptomless 278 
EG / M 
MelmAA 
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Ocl Nov 
tration 
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FLG 1. Urinary excretion of the histamine meta boli te methylimida-
zoleacetic acid (MelmAA) in 3 mastocytosis patients immecliately 
before, during . and after PUVA treatment. Dotted line: PUVA twice a 
week. Dashed line: PUVA once a week. Solid line: No treatment. Each 
va lue represents the mean excretion of 2 consecutive days after correc-
t ion for varying creatinine excretion. 
in EG compared to norma! controls [2] and other patients wi th 
mastocytosis [8]. In all 3 patients a significant (paired t-test) 
decrease in MeImAA excretion occurred within the first 2 mo 
of therapy, amounting to 2-4 mg/ 24 hr, whereafter the urinary 
excretion of MeImAA remained at about the same level (Fig 1). 
Three months after PUV A treatment had been stopped the 
excreti9n ofMeImAA in the uri ne was not significantly changed 
but patient GS had a mild pruTitus while the others were still 
free from symptoms. 
Urinary histamine was measured on altogether 54 occasions 
but, owing to the large intraindividual scatter, there was no 
evident decrease during therapy in any of the patients. The 
mean levels of histamine in the urine were 79 in patient GS 
(range 43-134),79 in patient LS (range 50-199) and 29 J.lg/24 hr 
in patient BG (range 13- 46). A significa nt correlation between 
histamine and MeImAA in the urine existed in the total mate-
rial (r 0.58, p < 0.01, n 28). 
In order to detect an acute histamine release during PUV A 
therapy urine was collected the day before treatment and 1-3 
days after treatment . T here was no significant increase in either 
histamine or MeImAA excretion dur ing .the day of PUV A 
treatment compared to the day before, neither was there any 
increase in histamine excretion during the second and third day 
after PUV A. However, in patient GS increased pruri tus was 
noticed for a few hours after the first 4 doses of psoralen and 
UV A-ligh t irradiation. T he other 2 patients never experienced 
any ac ute symptoms. 
An abundance of mast cells were seen in the histology sec-
tions before PUV A therapy in patients GS and LS, while only 
a few mast cells could be seen 10- 12 weeks after therapy (Fig 
Symptomless Symptomless 184 
FIG 2. Mast cell density of lesional skin in patient GS before (A) 
and 3 mo after PUVA thera py (B ). Arrows point at typical mast ceUs 
(G iemsa's reagent, reduced from x 150.) 
2), the number being considered not different fro m what is 
fo und in normal skin. 
DISCUSSION 
T he results of this study show a decrease in the urinary 
excretion of the main histamine metaboli te MelmAA during 
the fU'st 2 months after starting PUV A therapy. The decrease 
occurred concomitantly with the clinical improvement. T he 
treatment did not result in any complication typical of acute 
histamine release, such as headache, dizziness or hypotension. 
T he potential risks of shock were, however , considered in 
connection with the decision to lise small P UV A doses ini tially. 
There was no indication of histamine release associated with 
the treatment, as studied up to 72 hr after exposure to PUV A. 
P reviously, one patient with extensive cold urticaria has been 
investigated before and during attacks [9]. In this patient the 
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ur inary excretion of histamine and Melm~A increased about 
four times during days of symptoms, shoWIng the usefulness of 
these analyses for detection of acute histamine release. 
MeImAA is the major histamine metaboli te in the urine of 
normal subjects and also in patients with mastocytosis, as 
shown by injection of "'C-histamine in two patients [8] and "'C-
histidine in one patient [10] and analysis of labeled histamine 
and metabolites in the ur ine. Under steady-state conditions, 
i.e., without symptom~ of acute histamine release, most patients 
with UP studied in our laboratory who excreted abnormal 
amounts of MeImAA were fo und to have systemic manifesta-
tions of their disease (8). This was also true for the patients in 
this study who had mast cell infil trations in the skeleton, in the 
bone marrow and in the liver. We believe that the urinary 
excretion of MelmAA, as being the major histamine metabolite, 
is likely to reflect the tota.l mas~ cell popul.ation of the ma?t~­
cytosis patient. In one patient with gene.ra lIze.d mastocytos~s It 
has been possible to m easure the mean histamIne turnover tllne 
and calculate the total histamine pool of the body (10). The 
pool was found to be 700 I~g with a turnover rate of around 3.0 
mg histamine per day. ThiS strongly supports the hypothesIs 
that mastocytosis patients with increased amounts of histamine 
metabolites in the mine have an increased histamine pool, 
corresponding to the mast cell proliferation in the tissues. 
Fmthermore, in the present study the MelmAA-excretion in 2 
of the patients decreased but was not normalized, in spite of a 
normalized number of mast cells in the skin, which is consistent 
with a generalized mastocytosis in these patients and indicates 
a substantial histamine pool in other organs than the skin . 
Theoretically, a decreased urinary MelmAA after PUV A 
might be due to eithe.r a decreased. histamine. pool ~ the b~dy 
or a prolonged histamme tmnover t llTIe. The histological findIng 
of a reduction of the number of mast cells in the skin after 
treatment clearly indicates a decrease of the skin histamine 
pool. This interpretation is also in accordance with the generally 
accepted photobiological effects produced by psoralens, namely 
a photoconjugation to the pyrimidine bases of ~N A, which has 
a marked inhibitory effect of DNA syn theSIS [ll] and cell 
division (12). It is also possible that PUV A treatment causes an 
impaired histamine synthesis in the mast cells, but the fact that 
the interruption of PUV A treatment for 3 mo did not seem to 
replenish the histamine stores and increase MelmAA excretion 
is in accordance with a reduced mast cell population. 
Thus, the beneficial effect of PUV A in these UP patients 
seems to be associated with a diminished histamine turnover in 
the skin secondary to a reduced number of mast cells. However, 
the results do not prove that histamine is a causative factor of 
the prmitus in these patients. Indeed, it is common clinical 
experience that antihistamines seldom relieve the itch of UP. 
The new H 2-histamine antagonist cimetidine was also given to 
patient GS for several weeks without any effec.t on the prmitus. 
However, it must be remembered that the histamIne concen-
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trations in the skin of UP patients might be high in close 
vicini ty of the receptors eliciting the itch, so that the usual dose 
of ant ihistamines are ineffective. It was recently reported that 
oral administration of the an tiallergic drug disodium cromogly-
cate produced marked amelioration of pruritus and other symp-
toms in systemic mastocytosis [13). T his was achieved without 
any change in urinary histamine excretion and the authors 
concluded that disodium cromoglycate may act by mechanisms 
other than stabilization of mast cell membranes, bu t, as shown 
in this study, urinary histamine may not be a reliable indicator 
of changes in histamine turnover in mastocytosis patients. 
We ru'e indebted to Dr. Hiikan Gisslt~n , Viistra Frolunda sjukhus, 
Goteborg, for histological examination of the skin biopsies. We also 
tha nk Mrs Sol-Bri tt Burma n and Miss Ulla Blomgren for invalua ble 
assistance. 
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